

# Hasniza Zaman Huri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5469988/publications.pdf>

Version: 2024-02-01

65  
papers

1,360  
citations

430874

18  
h-index

361022

35  
g-index

67  
all docs

67  
docs citations

67  
times ranked

2715  
citing authors

#	ARTICLE	IF	CITATIONS
1	Antidepressant decision aid for major depressive disorder patients (ADAM): Development and pilot testing. <i>Patient Education and Counseling</i> , 2022, 105, 2466-2474.	2.2	4
2	Psychiatric pharmaceutical care service across Malaysian hospitals: results from a cross-sectional study. <i>BMC Health Services Research</i> , 2022, 22, 321.	2.2	1
3	Pharmacokineticâ€“Pharmacometabolomic Approach in Early-Phase Clinical Trials: A Way Forward for Targeted Therapy in Type 2 Diabetes. <i>Pharmaceutics</i> , 2022, 14, 1268.	4.5	6
4	Pharmacokinetics and Metabolomic Profiling of Metformin and <i>Andrographis paniculata</i> : A Protocol for a Crossover Randomised Controlled Trial. <i>Journal of Clinical Medicine</i> , 2022, 11, 3931.	2.4	0
5	Pharmacometabolomics of Metformin Demonstrated Insulin Sensitivity Related Pathways at Peak Plasma Concentration on Healthy Volunteers â€“ Preliminary Results. <i>Metabolism: Clinical and Experimental</i> , 2021, 116, 154536.	3.4	1
6	Association of YKL-40 Encoding Gene CHI3L1 rs946263 with Insulin Resistance and Severity of Coronary Artery Disease in Type 2 Diabetes Mellitus Patients. <i>Metabolism: Clinical and Experimental</i> , 2021, 116, 154520.	3.4	1
7	Single Nucleotide Polymorphism rs17173608 in the Chemerin Encoding Gene: Is It a Predictor of Insulin Resistance and Severity of Coronary Artery Disease in Non-Obese Type 2 Diabetes?. <i>Healthcare (Switzerland)</i> , 2021, 9, 623.	2.0	8
8	Retinol-Binding Protein-4â€“A Predictor of Insulin Resistance and the Severity of Coronary Artery Disease in Type 2 Diabetes Patients with Coronary Artery Disease. <i>Biology</i> , 2021, 10, 858.	2.8	7
9	Associations between Socio-Demographic Factors and Hypertension Management during the COVID-19 Pandemic: Preliminary Findings from Malaysia. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 9306.	2.6	10
10	Patient-Centred Communication in the Use of Antidepressants among People with Depression: A Scoping Review. <i>Sains Malaysiana</i> , 2021, 50, 161-170.	0.5	0
11	Pharmacogenetics of sulfonylurea-induced hypoglycemia in Type 2 diabetes patients: the SUCLINGEN study. <i>Pharmacogenomics</i> , 2021, 22, 1057-1068.	1.3	1
12	Medication Adherence for Haemophilia Patients: Outcome of Prophylaxis Treatment Intervention. <i>Healthcare (Switzerland)</i> , 2021, 9, 1702.	2.0	2
13	Clinical and genetic markers of erythropoietin deficiency anemia in chronic kidney disease (predialysis) patients. <i>Biomarkers in Medicine</i> , 2020, 14, 1099-1108.	1.4	2
14	Clinical and genetic predictors of secondary sulfonylurea failure in Type 2 diabetes patients: the SUCLINGEN study. <i>Pharmacogenomics</i> , 2020, 21, 587-600.	1.3	6
15	Global Scope of Hospital Pharmacy Practice: A Scoping Review. <i>Healthcare (Switzerland)</i> , 2020, 8, 143.	2.0	17
16	Heart Failure With Type 2 Diabetes Mellitus: Association Between Antihyperglycemic Agents, Glycemic Control, and Ejection Fraction. <i>Frontiers in Endocrinology</i> , 2020, 11, 448.	3.5	3
17	Pharmacist-led academic detailing improves statin therapy prescribing for Malaysian patients with type 2 diabetes: Quasi-experimental design. <i>PLoS ONE</i> , 2019, 14, e0220458.	2.5	8
18	&lt;p&gt;Drug-related problems in patients with rheumatoid arthritis&lt;/p&gt;. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 505-524.	2.0	34

#	ARTICLE	IF	CITATIONS
19	<p><p>Effectiveness and prescription pattern of lipid-lowering therapy and its associated factors among patients with type 2 diabetes mellitus in Malaysian primary care settings<p>. Therapeutics and Clinical Risk Management, 2019, Volume 15, 137-145.	2.0	13
20	Impact of educational outreach intervention on enhancing health care providers' knowledge about statin therapy prescribing in Malaysian patients with type 2 diabetes mellitus. Journal of Evaluation in Clinical Practice, 2018, 24, 521-527.	1.8	9
21	Reduced mitochondrial DNA content in lymphocytes is associated with insulin resistance and inflammation in patients with impaired fasting glucose. Clinical and Experimental Medicine, 2018, 18, 373-382.	3.6	5
22	Demographic, clinical and lifestyle predictors for severity of erectile dysfunction and biomarkers level in Malaysian patients. Brazilian Journal of Pharmaceutical Sciences, 2018, 54, .	1.2	0
23	Association of glycemic control with progression of diabetic retinopathy in type 2 diabetes mellitus patients in Malaysia. Brazilian Journal of Pharmaceutical Sciences, 2018, 54, .	1.2	1
24	Glycemic effects of simvastatin: Where do we stand?. Brazilian Journal of Pharmaceutical Sciences, 2018, 54, .	1.2	3
25	Development of a Strategic Tool for Shared Decision-Making in the Use of Antidepressants among Patients with Major Depressive Disorder: A Focus Group Study. International Journal of Environmental Research and Public Health, 2018, 15, 1402.	2.6	10
26	The Use of Antidepressants for Physical and Psychological Symptoms in Cancer. Current Drug Targets, 2018, 19, 1431-1455.	2.1	11
27	Altered circulating concentrations of active glucagon-like peptide (GLP-1) and dipeptidyl peptidase 4 (DPP4) in obese subjects and their association with insulin resistance. Clinical Biochemistry, 2017, 50, 746-749.	1.9	26
28	Chemokine Like Receptor-1 (CMKLR-1) Receptor: A Potential Therapeutic Target in Management of Chemerin Induced Type 2 Diabetes Mellitus and Cancer. Current Pharmaceutical Design, 2017, 23, 3689-3698.	1.9	31
29	Apoptotic induction and inhibition of NF- $\kappa$ B signaling pathway in human prostatic cancer PC3 cells by natural compound 2,2'-oxybis (4-allyl-1-methoxybenzene), biseugenol B, from <em>Litsea costalis</em>; an in vitro study. OncoTargets and Therapy, 2017, Volume 10, 277-294.	2.0	17
30	Drug-related problems in patients with erectile dysfunctions and multiple comorbidities. Therapeutics and Clinical Risk Management, 2017, Volume 13, 407-419.	2.0	6
31	Statin Therapy Prescribing for Patients with Type 2 Diabetes Mellitus: A Review of Current Evidence and Challenges. Journal of Pharmacy and Bioallied Sciences, 2017, 9, 80-87.	0.6	18
32	Factors associated with hypoglycemia episodes in hospitalized type 2 diabetes mellitus patients in a tertiary health facility in Malaysia. Tropical Journal of Pharmaceutical Research, 2016, 15, 1313.	0.3	1
33	Association of psychological factors, patients' knowledge, and management among patients with erectile dysfunction. Patient Preference and Adherence, 2016, 10, 807.	1.8	17
34	INDUCED PHOTODEGRADATION EFFECT ON THE FUNCTIONALIZED FE(III) COMPLEX ADDITIVE-POLY(VINYL Tj ETQg 0 0 0 rgBT /Overloc	0.4	0
35	Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells. Drug Design, Development and Therapy, 2016, Volume 10, 2443-2459.	4.3	191
36	Polyesters Based on Linoleic Acid for Biolubricant Basestocks: Low-Temperature, Tribological and Rheological Properties. PLoS ONE, 2016, 11, e0151603.	2.5	17

#	ARTICLE	IF	CITATIONS
37	Clinical and genetic predictors of dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes mellitus. <i>Pharmacogenomics</i> , 2016, 17, 867-881.	1.3	21
38	Genetic markers predicting sulphonylurea treatment outcomes in type 2 diabetes patients: current evidence and challenges for clinical implementation. <i>Pharmacogenomics Journal</i> , 2016, 16, 209-219.	2.0	24
39	Genetic polymorphisms associated with overweight and obesity in uncontrolled Type 2 diabetes mellitus. <i>Biomarkers in Medicine</i> , 2016, 10, 403-415.	1.4	33
40	Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?. <i>Cell Death and Disease</i> , 2016, 7, e2058-e2058.	6.3	238
41	Association of DPP4 Gene Polymorphisms with Type 2 Diabetes Mellitus in Malaysian Subjects. <i>PLoS ONE</i> , 2016, 11, e0154369.	2.5	21
42	Glycemic control and antidiabetic drugs in type 2 diabetes mellitus patients with renal complications. <i>Drug Design, Development and Therapy</i> , 2015, 9, 4355.	4.3	16
43	Celastrol Protects against Antimycin A-Induced Insulin Resistance in Human Skeletal Muscle Cells. <i>Molecules</i> , 2015, 20, 8242-8269.	3.8	29
44	Association between glycemic control and antidiabetic drugs in type 2 diabetes mellitus patients with cardiovascular complications. <i>Drug Design, Development and Therapy</i> , 2015, 9, 4735.	4.3	7
45	Serum Levels of Soluble CD26/Dipeptidyl Peptidase-IV in Type 2 Diabetes Mellitus and Its Association with Metabolic Syndrome and Therapy with Antidiabetic Agents in Malaysian Subjects. <i>PLoS ONE</i> , 2015, 10, e0140618.	2.5	19
46	Metabolomics – the complementary field in systems biology: a review on obesity and type 2 diabetes. <i>Molecular BioSystems</i> , 2015, 11, 1742-1774.	2.9	103
47	Mitochondrial dysfunction as a central event for mechanisms underlying insulin resistance: the roles of long chain fatty acids. <i>Diabetes/Metabolism Research and Reviews</i> , 2015, 31, 453-475.	4.0	65
48	Studies of the Impact of Occupational Exposure of Pharmaceutical Workers on the Development of Antimicrobial Drug Resistance. <i>Journal of Occupational Health</i> , 2014, 56, 260-270.	2.1	20
49	Drug-Related Problems in Patients with Benign Prostatic Hyperplasia: A Cross Sectional Retrospective Study. <i>PLoS ONE</i> , 2014, 9, e86215.	2.5	22
50	Sliding-Scale versus Basal-Bolus Insulin in the Management of Severe or Acute Hyperglycemia in Type 2 Diabetes Patients: A Retrospective Study. <i>PLoS ONE</i> , 2014, 9, e106505.	2.5	9
51	Pancreatic gene variants potentially associated with dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes. <i>Pharmacogenomics</i> , 2014, 15, 235-249.	1.3	5
52	A Prospective Cohort Study of IRS Genes Polymorphisms in Type 2 Diabetes Mellitus Patients during Severe/Acute Hyperglycemia Phase. 2: Association with Glycemic Control. <i>Tropical Journal of Pharmaceutical Research</i> , 2014, 13, 903.	0.3	1
53	Factors Associated with Utilization of Dipeptidyl-4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Retrospective Study. <i>International Journal of Endocrinology</i> , 2014, 2014, 1-7.	1.5	3
54	Amelioration of Mitochondrial Dysfunction-Induced Insulin Resistance in Differentiated 3T3-L1 Adipocytes via Inhibition of NF- $\kappa$ B Pathways. <i>International Journal of Molecular Sciences</i> , 2014, 15, 22227-22257.	4.1	27

#	ARTICLE	IF	CITATIONS
55	Factors Associated with Treatment Response to Antidiabetic Agents in Compliant Type 2 Diabetes Mellitus Patients: A Brief Summary of 5-Year Data. <i>Tropical Journal of Pharmaceutical Research</i> , 2014, 13, 429.	0.3	0
56	Effect of Interaction between Polymorphisms in Insulin Receptor Substrate Genes in Type 2 Diabetes Mellitus Patients with Severe/Acute Hyperglycemia. <i>Tropical Journal of Pharmaceutical Research</i> , 2014, 13, 889.	0.3	0
57	A Prospective Cohort Study on IRS Gene Polymorphisms in Type 2 Diabetes Mellitus Patients during Severe/Acute Hyperglycemia Phase 1: Association with Insulin Resistance. <i>Tropical Journal of Pharmaceutical Research</i> , 2014, 13, 895.	0.3	0
58	Palm Olein as Renewable Raw Materials for Industrial and Pharmaceutical Products Applications: Chemical Characterization and Physicochemical Properties Studies. <i>Advances in Materials Science and Engineering</i> , 2014, 2014, 1-5.	1.8	13
59	Oral drug treatments in patients with erectile dysfunction and multiple comorbidities: a retrospective observational study. <i>BMJ Open</i> , 2014, 4, e005381-e005381.	1.9	6
60	Drug-related problems in type 2 diabetes mellitus patients with dyslipidemia. <i>BMC Public Health</i> , 2013, 13, 1192.	2.9	49
61	Drug related problems in type 2 diabetes patients with hypertension: a cross-sectional retrospective study. <i>BMC Endocrine Disorders</i> , 2013, 13, 2.	2.2	62
62	Potential Biomarkers of Insulin Resistance and Atherosclerosis in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease. <i>International Journal of Endocrinology</i> , 2013, 2013, 1-11.	1.5	64
63	Optimisation of glycaemic control during episodes of severe/acute hyperglycaemia in patients with type 2 diabetes mellitus. <i>International Journal of Clinical Pharmacy</i> , 2012, 34, 863-870.	2.1	14
64	Use of Antiplatelet Agents for Primary and Secondary Prevention of Cardiovascular Disease Amongst Type 2 Diabetic Patients. <i>Journal of Pharmacy Practice</i> , 2008, 21, 287-301.	1.0	2
65	A Clinical Practice Guideline Summary for Pharmacological Management of Adults with Major Depressive Disorder in Malaysia. <i>Journal of Pharmaceutical Research International</i> , 0, , 405-411.	1.0	0